CSIMarket
 
Mylan N.v.  (MYL)
Other Ticker:  
 
 

Mylan N.v.'s Suppliers Performance

MYL's Supply Chain

 
MYL Costs vs Sales of Suppliers Growth Mylan N.v.'s Suppliers realized sales deteriorated by -32.13 % compare to the same quarter a year ago, sequentially sales grew by 13.85 %, while their net profit margin fell to 12.31 % year on year, Mylan N.v.'s Suppliers improved sequentially profit margin to 13.85 %,

More on MYL Suppliers




Mylan N.v.'s Suppliers realized sales deteriorated by -32.13 % compare to the same quarter a year ago, sequentially sales grew by 13.85 %, while their net profit margin fell to 12.31 % year on year, Mylan N.v.'s Suppliers improved sequentially profit margin to 13.85 %,

More on MYL Suppliers




Mylan N.v.'s Comment on Supply Chain


We own or license a number of patents in the U.S. and other countries covering certain products and have also developed brand names and trademarks for other products. Generally, the brand pharmaceutical business relies upon patent protection to ensure market exclusivity for the life of the patent. We consider the overall protection of our patents, trademarks and license rights to be of significant value and act to protect these rights from infringement. However, our business is not dependent upon any single patent, trademark or license.

In the branded pharmaceutical industry, the majority of an innovative product’s commercial value is usually realized during the period in which the product has market exclusivity. In the U.S. and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales. The rate of this decline varies by country and by therapeutic category; however, following patent expiration, branded products often continue to have market viability based upon the goodwill of the product name, which typically benefits from trademark protection.

An innovator product’s market exclusivity is generally determined by two forms of intellectual property: patent rights held by the innovator company and any regulatory forms of exclusivity to which the innovator is entitled.

Patents are a key determinant of market exclusivity for most branded pharmaceuticals. Patents provide the innovator with the right to lawfully exclude others from practicing an invention related to the medicine. Patents may cover, among other things, the active ingredient(s), various uses of a drug product, pharmaceutical formulations, drug delivery mechanisms and processes for (or intermediates useful in) the manufacture of products. Protection for individual products extends for varying periods in accordance with the expiration dates of patents in the various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent, its scope of coverage and the availability of meaningful legal remedies in the country.

Market exclusivity is also sometimes influenced by regulatory intellectual property rights. Many developed countries provide certain non-patent incentives for the development of medicines. For example, the U.S., the EU and Japan each provide for a minimum period of time after the approval of a new drug during which the regulatory agency may not rely upon the innovator’s data to approve a competitor’s generic copy. Regulatory intellectual property rights are also available in certain markets as incentives for research on new indications, on orphan drugs and on medicines useful in treating pediatric patients. Regulatory intellectual property rights are independent of any patent rights and can be particularly important when a drug lacks broad patent protection. However, most regulatory forms of exclusivity do not prevent a competitor from gaining regulatory approval prior to the expiration of regulatory data exclusivity on the basis of the competitor’s own safety and efficacy data on its drug, even when that drug is identical to that marketed by the innovator.

We estimate the likely market exclusivity period for each of our branded products on a case-by-case basis. It is not possible to predict the length of market exclusivity for any of our branded products with certainty because of the complex interaction between patent and regulatory forms of exclusivity and inherent uncertainties concerning patent litigation. There can be no assurance that a particular product will enjoy market exclusivity for the full period of time that we currently estimate or that the exclusivity will be limited to the estimate.

In addition to patents and regulatory forms of exclusivity, we also market products with trademarks. Trademarks have no effect on market exclusivity for a product, but are considered to have marketing value. Trademark protection continues in some countries as long as used; in other countries, as long as registered. Registration is for fixed terms and may be renewed indefinitely.


Mylan N.v.'s Comment on Supply Chain


We own or license a number of patents in the U.S. and other countries covering certain products and have also developed brand names and trademarks for other products. Generally, the brand pharmaceutical business relies upon patent protection to ensure market exclusivity for the life of the patent. We consider the overall protection of our patents, trademarks and license rights to be of significant value and act to protect these rights from infringement. However, our business is not dependent upon any single patent, trademark or license.

In the branded pharmaceutical industry, the majority of an innovative product’s commercial value is usually realized during the period in which the product has market exclusivity. In the U.S. and some other countries, when market exclusivity expires and generic versions of a product are approved and marketed, there can often be very substantial and rapid declines in the branded product’s sales. The rate of this decline varies by country and by therapeutic category; however, following patent expiration, branded products often continue to have market viability based upon the goodwill of the product name, which typically benefits from trademark protection.

An innovator product’s market exclusivity is generally determined by two forms of intellectual property: patent rights held by the innovator company and any regulatory forms of exclusivity to which the innovator is entitled.

Patents are a key determinant of market exclusivity for most branded pharmaceuticals. Patents provide the innovator with the right to lawfully exclude others from practicing an invention related to the medicine. Patents may cover, among other things, the active ingredient(s), various uses of a drug product, pharmaceutical formulations, drug delivery mechanisms and processes for (or intermediates useful in) the manufacture of products. Protection for individual products extends for varying periods in accordance with the expiration dates of patents in the various countries. The protection afforded, which may also vary from country to country, depends upon the type of patent, its scope of coverage and the availability of meaningful legal remedies in the country.

Market exclusivity is also sometimes influenced by regulatory intellectual property rights. Many developed countries provide certain non-patent incentives for the development of medicines. For example, the U.S., the EU and Japan each provide for a minimum period of time after the approval of a new drug during which the regulatory agency may not rely upon the innovator’s data to approve a competitor’s generic copy. Regulatory intellectual property rights are also available in certain markets as incentives for research on new indications, on orphan drugs and on medicines useful in treating pediatric patients. Regulatory intellectual property rights are independent of any patent rights and can be particularly important when a drug lacks broad patent protection. However, most regulatory forms of exclusivity do not prevent a competitor from gaining regulatory approval prior to the expiration of regulatory data exclusivity on the basis of the competitor’s own safety and efficacy data on its drug, even when that drug is identical to that marketed by the innovator.

We estimate the likely market exclusivity period for each of our branded products on a case-by-case basis. It is not possible to predict the length of market exclusivity for any of our branded products with certainty because of the complex interaction between patent and regulatory forms of exclusivity and inherent uncertainties concerning patent litigation. There can be no assurance that a particular product will enjoy market exclusivity for the full period of time that we currently estimate or that the exclusivity will be limited to the estimate.

In addition to patents and regulatory forms of exclusivity, we also market products with trademarks. Trademarks have no effect on market exclusivity for a product, but are considered to have marketing value. Trademark protection continues in some countries as long as used; in other countries, as long as registered. Registration is for fixed terms and may be renewed indefinitely.



MYL's Suppliers Net profit fell by MYL's Suppliers Net margin fell in Q2 to
-35.4 % 12.31 %


Mylan N.v.'s Suppliers Sales Growth in Q2 2019 by Industry

Suppliers in Chemical Manufacturing Industry -7 %   
Suppliers in Containers & Packaging Industry -2.94 %   
Suppliers in Iron & Steel Industry      9.58 %
Suppliers in Miscellaneous Fabricated Products Industry -0.97 %   
Suppliers in Miscellaneous Manufacturing Industry      3.53 %
Suppliers in Industrial Machinery and Components Industry -5.79 %   
Suppliers in Food Processing Industry -2.28 %   
Suppliers in Oil & Gas Integrated Operations Industry      1.86 %
Suppliers in Biotechnology & Drugs Industry    
Suppliers in Communications Equipment Industry      7.03 %
Suppliers in Scientific & Technical Instruments Industry      3.92 %
Suppliers in Semiconductors Industry      1.26 %
     
• MYL Suppliers Valuation • MYL Segment Rev. Growth • MYL Segment Inc. Growth • MYL Suppliers Mgmt. Effect.





MYL's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME TICKER MARKET CAP REVENUES INCOME EMPLOYEES
Mylan N.v. MYL 0 11,535 34 25,000
Bemis Co Inc BMS 5,239 4,064 239 19,100
Corning Inc GLW 21,717 11,503 960 34,600
Dow Inc. DOW 107,719 41,768 -1,672 53,000
Eastman Chemical Co EMN 10,144 9,611 974 15,000
Meadwestvaco Corp MWV 0 9,601 838 16,000
MILLIPORE CORPORATION MIL 0 0 0 0
PALL CORPORATION PLL 0 0 0 10,400
Sigma Aldrich Corp SIAL 0 4,724 491 9,300
Thermo Fisher Scientific Inc. TMO 135,316 25,220 3,592 51,000
Waters Corp WAT 17,249 2,342 27 6,200
Atyr Pharma Inc LIFE 16 0 -24 0
Illinois Tool Works Inc ITW 61,167 14,109 2,521 49,000
Air Products & Chemicals Inc APD 56,578 8,935 1,750 19,700
Fmc Corporation FMC 13,964 4,632 518 5,900
Airgas Inc ARG 0 0 0 17,000
Danaher Corporation DHR 118,059 20,437 2,486 71,000
Ashland Global Holdings Inc. ASH 87 2,450 585 11,000
Avery Dennison Corp AVY 11,359 7,066 238 26,000
Stericycle Inc SRCL 5,950 3,387 -385 16,718
Om Group Inc OMG 0 1,103 -80 6,200
Darling Ingredients Inc. DAR 4,863 3,358 120 10,000
Cryoport, Inc. CYRX 652 30 -20 31
Synalloy Corporation SYNL 110 310 -2 411
Albemarle Corporation ALB 9,825 3,519 644 5,000
Chemtura Corp CHMT 0 1,462 -893 2,500
Huntsman Corporation HUN 4,761 7,572 598 15,000
Quaker Chemical Corporation KWR 2,993 954 24 2,020
Omnova Solutions Inc OMN 464 758 8 2,100
Stepan Co SCL 2,345 1,901 108 2,073
Westlake Chemical Corporation WLK 7,913 7,858 275 8,870
Westlake Chemical Partners Lp WLKP 821 1,269 324 141
Barnes Group Inc B 3,396 1,505 156 5,036
Trecora Resources TREC 162 272 -1 310
Photronics Inc PLAB 990 551 40 1,475
SUBTOTAL 603,857 202,268 14,441 492,085


             
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

AITB's Profile

Stock Price

AITB's Financials

Business Description

Fundamentals

Charts & Quotes

AITB's News

Suppliers

AITB's Competitors

Customers & Markets

Economic Indicators

AITB's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2020 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071